Off-label uses of denosumab in metabolic bone diseases
Abstract
No abstract availableKeywords
This publication has 142 references indexed in Scilit:
- Denosumab: a potential new and innovative treatment option for aneurysmal bone cystsEuropean Spine Journal, 2013
- Pathogenesis of Langerhans Cell HistiocytosisAnnual Review of Pathology: Mechanisms of Disease, 2013
- Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-NetOrphanet Journal of Rare Diseases, 2013
- Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumabTherapeutics and Clinical Risk Management, 2012
- A single-dose study of denosumab in patients with various degrees of renal impairmentJournal of Bone and Mineral Research, 2012
- Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosisBone, 2011
- Effects of denosumab on fracture and bone mineral density by level of kidney functionJournal of Bone and Mineral Research, 2011
- Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosisHaematologica, 2010
- Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget’s diseaseJournal of Bone and Mineral Metabolism, 2010
- Diagnosis and management of hypocalcaemiaBMJ, 2008